

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-320US

In Re Application Of: **MURPANI et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/539,129	12/16/2003	TBA	026815	TBA	

Title: **AN EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF PHENYTOIN SODIUM**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-320US

In Re Application of: **MURPANI et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/539,129	12/16/2003	TBA	026815	TBA	

Title: **AN EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF PHENYTOIN SODIUM**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912
as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.


Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa
_____ (Date)
_____ Signature
_____ Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on
_____ (Date)
_____ Signature of Person Mailing Correspondence
_____ Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


Signature

Dated: April 10, 2006

William D. Hare
Reg. No. 44,739
Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, NJ 08540
Tel.: (609) 720-5378
Fax: (609) 514-9779

CC:

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-320US	Serial No.: 10/539,129
	Applicants: MURPANI <i>et al.</i>	
	Filed: 6/15/2005	Group:

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	2,409,754	10/22/1946	Henze	260	309.5	
	A2	4,642,316	2/10/1987	Fawzi <i>et al.</i>	514	398	
	A3	4,696,814	9/29/1987	Kao <i>et al.</i>	424	80	
	A4	6,274,168	8/14/2001	Addicks <i>et al.</i>	424	451	
	A5	6,620,432	9/16/2003	Addicks <i>et al.</i>	424	451	

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	EP 0 250 038	12/23/1987	EPO	A61K	9/52	
	B2	EP 0 439 858	8/7/1991	EPO	A61K	31/415	
	B3	WO 92/15285	9/17/1992	PCT	A61K	9/20	
	B4	WO 02/092056	11/21/2002	PCT	A61K	9/16	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	C1	"1259. Bifluranol.", <i>The Merck Index</i> , 12th Edition, p. 204 (1996)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	